Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
S. S. Akhand, S. C. Purdy, Z. Liu, J. Anderson, C. Willey, M. Wendt
This study shows that FGFR1 promotes T-DM1 resistance and tumor recurrence in HER2+ breast cancer, suggesting FGFR inhibitors like FIIN4 could be combined with T-DM1 for better treatment.
bioRxiv · Aug 9, 2019Cancer Biology